✦ LIBER ✦

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors : Results of a multicenter phase 2 trial

✍ Scribed by Andrew J. Wagner; John M. Goldberg; Steven G. DuBois; Edwin Choy; Lee Rosen; Alberto Pappo; James Geller; Ian Judson; David Hogg; Neil Senzer; Ian J. Davis; Feng Chai; Carol Waghorne; Brian Schwartz; George D. Demetri

Book ID: 112067187
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 307 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.27582

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 multicenter study of tivantini

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

✍ Darren R. Feldman, Lawrence H. Einhorn, David I. Quinn, Yohann Loriot, Johnathan 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 240 KB

A phase II trial of a selective c-Met in

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

✍ Kang, Yoon-Koo; Muro, Kei; Ryu, Min-Hee; Yasui, Hirofumi; Nishina, Tomohiro; Ryo 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 234 KB

651 POSTER A Phase 1 dose escalation stu

651 POSTER A Phase 1 dose escalation study of ARQ 197, a selective inhibitor of the c-Met receptor in patients with metastatic solid tumors

✍ L. Rosen; A. Garcia; M. Mulay; C. Cunningham; J. Nemunaitis; N. Senzer; C. Li; A 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 50 KB

608 Phase I Dose-escalation Trial of a S

608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors

✍ Naing, A.; Mita, M.; Komarnitsky, P.; Milner, A.; von Richter, O.; Ogden, J.; Pi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB

1207 Results of study PX-171–007 a phase

1207 Results of study PX-171–007 a phase 1b/2 study of carfilzomib, a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors

✍ M. Gordon; J. Infante; K.P. Papadopoulos; P. Lee; E. Sausville; D. Mendelson; A. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

A Multicenter Phase II Trial of ZD6474,

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Previously Treated Metastatic Breast Cancer

✍ Dickler, M.N. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB